Gene Technology Amendment Regulations 2009 (No. 1)

Overview

The Gene Technology Act 2000, enacted by the Commonwealth Parliament, was established to create a nationally consistent scheme aimed at safeguarding public health and the environment by identifying and managing risks associated with gene technology and genetically modified organisms. The Act designates the Gene Technology Regulator as the statutory office holder responsible for administering the legislative framework. The Gene Technology Amendment Regulations 2009 (No. 1) were introduced to address the need for inspectors from the Gene Technology Regulatory Scheme to perform functions under the new Security Sensitive Biological Agents (SSBA) Regulatory Scheme, thereby aligning with the policy recommendations outlined in the Council of Australian Governments' (COAG) 2006 Report on the Regulation and Control of Biological Agents. The Gene Technology Ministerial Council, comprising state, territory, and Australian government ministers, has approved these Regulations, ensuring they meet the necessary intergovernmental standards and reflect the policy objective of utilising existing regulatory resources to enhance biosecurity measures. These Regulations amend the Gene Technology Regulations 2001 to enable inspectors from the Office of the Gene Technology Regulator (OGTR) to serve as SSBA inspectors, following consultations with relevant stakeholders and entities likely to be affected by the SSBA Regulatory Scheme. The amendments are necessary to align the legal authority of the Gene Technology Regulator with the expanded role of providing inspectors for the SSBA Regulatory Scheme, which is itself part of the legislative response to the COAG Report, and supported by the National Health Security Act 2007 and associated regulations. The Regulations are a legislative instrument under the Legislative Instruments Act 2003 and will come into effect upon registration on the Federal Register of Legislative Instruments.

Scope and Application

The Gene Technology Act 2000 applies to dealings with genetically modified organisms to ensure the protection of human health and the environment in Australia. This Act, administered by the Gene Technology Regulator, establishes a framework for managing risks associated with gene technology, ensuring that any potential hazards are identified and controlled. The legislation extends to all entities and persons engaged in activities involving genetically modified organisms, including research, commercial production, and import/export transactions. The Act's reach is national, as it operates under a scheme consistent across Australia, with the Regulator holding statutory powers to enforce compliance. The Act also allows for the creation of subordinate instruments to further specify regulatory requirements, such as the Gene Technology Amendment Regulations 2009 (No. 1), which facilitate the integration of inspectors from the Gene Technology Regulatory Scheme into the new Security Sensitive Biological Agents (SSBA) Regulatory Scheme. This amendment ensures that the Gene Technology Regulator can provide inspectors to enforce the SSBA Regulatory Scheme, addressing security concerns related to hazardous biological materials. There are no stated exclusions or thresholds in the Act itself; however, the scope of the regulations can be refined through subordinate legislation, ensuring the regulatory framework remains effective and responsive to emerging risks.

Key Provisions

The main operative sections of the Gene Technology Amendment Regulations 2009 (No. 1) revolve around the conferral of specific functions to the Gene Technology Regulator (GTR) to facilitate the integration of inspectors from the Gene Technology Regulatory Scheme into the Security Sensitive Biological Agents (SSBA) Regulatory Scheme. Section 3 of the Regulations amends the Gene Technology Regulations 2001 to provide that the GTR can now make available inspectors to be appointed as SSBA inspectors. This amendment is crucial for ensuring that the inspection functions under the SSBA Regulatory Scheme are carried out effectively, leveraging the existing expertise and framework of the Gene Technology Regulatory Scheme. The obligations imposed by the Regulations on the GTR primarily involve the appointment and deployment of inspectors for the SSBA Regulatory Scheme. By virtue of section 3, the GTR is tasked with making inspectors available for SSBA inspections, thereby ensuring that the regulated community complies with the stringent security measures required for handling sensitive biological agents. This function necessitates that the GTR maintain a pool of qualified inspectors who can be seconded to the SSBA scheme as needed, and that these inspectors are adequately trained and authorised to perform inspections under both regulatory schemes. In terms of potential breaches and their consequences, while the Regulations themselves do not explicitly state specific offences or penalties, it is important to note that any failure by the GTR to comply with its obligations under the amended Regulations could potentially lead to non-compliance with the SSBA Regulatory Scheme. Such non-compliance might attract penalties or enforcement actions under the National Health Security Act 2007, which governs the SSBA Regulatory Scheme. Additionally, any failure by entities subject to inspection under the SSBA scheme to comply with the inspection requirements could result in enforcement actions under the National Health Security Regulations 2008, including fines or other civil penalties as stipulated by the Act. The precise penalties would depend on the nature and severity of the non-compliance, as well as the specific provisions of the NHS Act and its supporting regulations.